However, genetic polymorphisms in CQ and PQ metabolizing enzymes that might influence drug availability and response to malaria therapeutic regimen were never investigated; therefore, the present study aims to evaluate whether genetic polymorphisms in G6PD, CYP1A2, CYP2C8, CP2C9, CP3A4 and CYP3A5 influence P. vivax malaria treatment response. This evidence concerns the gene CYP2C8 and malaria.